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Abstract As the current staging system is imprecise for esti-
mating prognosis of early stage non-small cell lung cancer
(NSCLC), it is important to identify other methods for
selecting high-risk patients after failed surgical treatment.
The aim of the study was to evaluate the expression of 23
genes as putative prognostic markers in early stage NSCLC.
The study was performed on 109 pairs of tumor and matched
unaffected lung tissue surgical specimens taken from stage I
and II NSCLC patients. We evaluated the mRNA level of 23
genes using the real-time PCR method. The difference in the
expression between the tumor and normal tissue for each gene
was analyzed using a general linear model. The influence of
gene expression on survival was analyzed by using the
proportional hazards model. Eighteen out of the 23 genes
showed statistically significant differences in expression be-
tween the tumor and non-tumor tissue. For 12 genes (ITGB1,
ITGB3, CXCL1, CXCL8, CXCL9, CXCL10, CXCL11, CXCR3,
CXCR4, TNF,CHKA, AGFG1, andCTC1), the expression was
lower, and for six genes (ITGA5, IL8, IL6, CXCL2, CXCL3,
andCXCL12), it was higher in the tumor tissue as compared to
the matched normal tissue. Expression changes were more
pronounced in squamous cell carcinomas than in adenocarci-
nomas or large cell carcinomas. Of all the analyzed genes,
only CXCL5 was found to statistically significantly (p=0.04)
influence both overall and disease-free survival. Among the
23 genes previously suggested to be relevant for early staged
NSCLC patients’ postoperative outcome, only CXCL5
showed a statistically significant prognostic effect.
Keywords Non-smallcell lungcancer .Prognosis .Molecular
markers . CXCL5
Introduction
Lung cancer is the most common cause of cancer deaths
worldwide, and approximately 80 % of the patients have
non-small cell lung cancer (NSCLC). Current mode of lung
cancer therapy mainly depends on the TNM disease staging
and tumor histological classification, and the treatment-of-
choice for early stage NSCLCs constitutes radical surgery.
However, about 30 to 50 % of early stage NSCLC patients
(in stages I and II) die within 5 years after radical surgical
treatment as a consequence of disease recurrence or metasta-
sis. Results of recent studies have shown some benefit of
adjuvant chemotherapy in surgically treated NSCLC patients
with 5-year survival advantage of 4–15 % [1]. However, the
factors that might help to prospectively identify patients who
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will most likely benefit from any or specific type of postop-
erative chemotherapy remain unknown, especially among
individuals with stages I–IIA disease.
It has been suggested that evaluation of molecular bio-
markers for prediction and prognostics could improve the
management of patients with NSCLC [2]. Recent advances
in genomics and proteomics of lung cancer have established new
candidate markers with potential clinical value. Based on the
results of high-throughput microarray and real-time PCR data,
several prognostic gene expression signatures have been created
to stratify patients for appropriate treatment; however, the pro-
posed gene sets differ significantly from one another. Thus,
further studies on gene expression signature as well as verifica-
tion of previously reported data have to be performed [3].
The quantitative real-time PCR (qRT-PCR) seems to be the
most appropriate method for both the microarray-based prog-
nostic gene expression signatures validation and their further
practical application in the clinics [4]. Recently, the capabili-
ties of qRT-PCR have been expanded with the development of
low density gene expression arrays that allow simultaneous
examination of multiple, user-defined genes [5].
In the current study, we evaluated the expression of 23 genes
reported previously as putative prognostic markers in NSCLC.
The genes used for evaluation were defined according to a
number of microarray-based studies (three genes: AGFG1/
HRB, STC1, SLC2A1 that overlap between NSCLC prognos-
tic signatures), comprehensive real-time PCR analyses, and/or
protein-evaluating assays [6–17]. The selected genes are listed
in Table 1. We used low density microarray approach to simul-
taneously evaluate the expression of all the analyzed genes and
to compare gene expression level in tumor and corresponding
non-tumor lung tissues. We also analyzed the association be-
tween the expression level of the particular genes and the
overall survival (OS) and disease-free survival (DFS).
Materials and Methods
Patients and samples
The study was performed on 109 pairs of tumor and matched
unaffected lung tissue specimens obtained from early stage
NSCLC (stages I and II) patients who underwent a curative
surgery at the Bialystok Medical University Hospital. All
patients gave the written informed consent for specimen col-
lection and clinicopathological data processing. The study
was approved by the ethics committee of the university.
All patients underwent complete resection of the tumor and
mediastinal lymphnodes andwere followedup for at least 3 years
or until death. None of them received chemo- or radiotherapy
before or after the surgery. The OS was estimated as the time
from the date of the surgery to the date of death (event) or of the
last control visit (censoring). The DFS was defined as the time
from the date of surgery to the date of disease relapse or death
(events), whichever occurred first, or to the date of the last visit
(censoring). Patients’ clinicopathological characteristics (age,
gender, histological type, and pathological TNM staging) are
summarized in the “Results” section.
Tissue samples were collected intraoperatively and proc-
essed immediately after surgical removal; after the macro-
scopic visual assessment, the pieces of tumor tissue and un-
affected lung tissue from the same lobe or lung of the patient
were frozen in liquid nitrogen followed by storage at −80 °C.
Prior to processing, the cryo-sections of frozen tissue speci-
mens were stained with hematoxylin–eozyn and evaluated by
an experienced pathologists (LC) to confirm the suitability of
tumor cell content. Only the tumor samples which contained
at least 50% of tumor cells on a microscopic section as well as
unaffected lung tissue samples without malignant cells were
used for further processing.
RNA extraction
Total RNAwas isolated from tissue specimens using magnetic
extraction method. Briefly, about 40–50 mg of frozen tissue
was disrupted in 500 μl of Lysis Buffer (Biomerieux, France)
with a TissueRupter (Qiagen, Germany) and incubated with
Proteinase K (Sigma-Aldrich, Germany) for 2 h in 56 °C.
Nucleic acids from deproteinated cell lysates were extracted
automatically on EasyMag machine (Biomerieux, France)
according to the producer’s protocol. The 100-μl resulting
RNA extracts were stored in −80 °C before further processing.
The concentration of the RNA in the extracts was deter-
mined on the NanoDrop 2000c spectrophotometer (Thermo
Scientific, UK) and about 500 ng of the RNAwas transcripted
into cDNA in a reaction with High Capacity RNA-to-cDNA
Master Mix (Applied Biosystems, Foster City, CA) according
the producer’s recommendations.
mRNA expression level
An mRNA expression level of 23 genes was evaluated in the
tumor and unaffected lung tissues with the comparative real-
time PCR (RT-PCR) method using a TaqMan low density
array analysis [18]. Ribosomal 18S RNA gene with a relative-
ly low level of the expression variability in lung tissue [9] was
used to normalize for the differences in the input cDNA
concentration. For each sample, the amplification of all the
transcripts was performed simultaneously in the MicroFluid
Cards (Applied Biosystems) that contained manufactory load-
ed and dried commercially available primers/probe sets for
gene expression examination (Assays-on-Demand, Applied
Biosystems). The Assay-on-Demand accession numbers are
summarized in Supplementary Table 1. Each channel of a card
was loaded with 100 μl of the reaction mixture containing
50 μl 2XTaqMan Gene Expression Master Mix (Applied
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Table 1 List of the genes analyzed in the study
No. Gene symbol Gene Ida Gene product official name (aliases) Gene product functions References
1. AGFG1/HRB 5175 Arf-GAP domain and FG




2. STC1 11373 Stanniocalcin 1 Probably regulates calcium/phosphate
transport and metabolism
[6, 8]
3. SLC2A1 11005 Solute carrier family member 2
(facilitated glucose transporter),
member 1
A major glucose transporter in the
mammalian blood–brain barrier
[6, 8, 9]
4. CHKA 1937 Choline kinase alpha Catalyzes the first step in
phosphatidylcholine
biosynthesis and contributes to
phosphatidylethanolamine biosynthesis
[10]




leukocytes at sites of inflammation;
stimulates angiogenesis
[11, 12]




leukocytes at sites of inflammation;
stimulates angiogenesis
[11]
7. CXCL3 4604 Chemokine (C-X-C motif)
ligand 3 (melanoma growth
stimulating activity, gamma)
Recruits neutrophil polymorphonuclear
leukocytes at sites of inflammation;
stimulates angiogenesis
[11, 12]




Involved in neutrophil activation;
stimulates angiogenesis
[11]
9. CXCL6 10643 Chemokine (C-X-C motif)
ligand 6 (granulocyte hemotactic
peptide-2 (GCP-2))




10. CXCR2 6027 Chemokine (C-X-C motif)
receptor 2 (interleukin-8
receptor, beta)
Membrane receptor that binds chemokines
CXCL6 and CXCL8 with high affinity
[11]
11. CXCR3 4540 Chemokine (C-X-C motif)
receptor 3




12. CXCR4 2561 Chemokine (C-X-C motif)
receptor 4
Membrane receptor specific for
chemokine CXCL12/SDF-1.
Important in the metastatic
behavior of solid tumors
[11, 13, 14]
13. CXCL9 7098 Chemokine (C-X-C motif)
ligand 9 (monokine induced
by gamma interferon (MIG))
Is a Th1-cell attracting chemokine;
blocks angiogenesis
[11, 12]
14. CXCL10 10637 Chemokine (C-X-C motif)
ligand 10 (10 kDa interferon-
gamma-induced protein
(IP-10))
Is chemotactic for monocytes and
T\ lymphocytes, has pleiotropic
effects on these cells, and blocks
angiogenesis
[11]
15. CXCL11 10638 Chemokine (C-X-C motif) ligand 11
(0Interferon-inducible T cell
alpha chemoattractant (I-TAC))
Is a chemoattractant to interleukin-
activated T cells; blocks angiogenesis
[11]
16. CXCL12 10672 Chemokine (C-X-C motif) ligand
12 (Stromal cell-derived factor 1
(SDF-1))
Is a chemoattractant to T lymphocytes
and monocytes
[11, 14]
17. IL10 5962 Interleukin-10 (cytokine synthesis
inhibitory factor (CSIF))
Inhibits the synthesis of a number
of cytokines including interferon-
gamma, IL-2, IL-3,TNF, and
Gm-CSF produced by activated
macrophages and by helper T cells
[15, 16]
18. IL6 6018 Interleukin-6 (interferon, beta 2
(IFNB2))
A cytokine that functions in inflammation
and the maturation of B cells and is
a potent inducer of the acute phase
response
[15]
19. IL8 6025 Interleukin-8 (Chemokine
(C-X-C motif) ligand 8(CXCL8))
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Biosystems) and 20 μl of a cDNA solution (corresponding to
100 ng of total RNA). The amplification was performed on a
ABI PRISM 7900HT Sequence Detection System equipped
with the SDS v.2.4 software for baseline and Ct calculations.
The cycling conditions were as follows: 50 °C for 2 min
followed by 95 °C for 10 min hold and 40 cycles of 95 °C
for 15 s and 60 °C for 60 s. Each sample was analyzed in
duplicate. To minimize run-to-run variations, the same card
was used to evaluate gene expression in tumor and matched
normal lung tissues from a particular patient. The raw Ct data
from each run were exported into the Excel software for
further processing. All gene expression measurements were
analyzed on the logarithmic scale (log-expression). For each
of the 23 analyzed genes, the two measurements were aver-
aged and the ratio, i.e., fold change of the averages for the
tumor and normal tissues was computed.
Statistical analysis
The difference in the log-expression between the tumor and
normal tissue (log-fold-change) for each gene was analyzed
by using a linear mixed effects model (with a random tissue
effect) taking into account the correlation between the repeat-
ed expressionmeasurements obtained for a single patient [19].
OS and DFS probabilities were estimated by using the
Kaplan-Meier method. The median follow-up time was esti-
mated by using the “reverse” Kaplan-Meier method [20]. The
influence of clinical factors and gene expression on OS and
DFS was analyzed by using the proportional hazards model.
First, a model including age, sex, TNM stage, and histological
type was fitted to the data. The model was then simplified by
retaining only the factors showing a statistically significant
effect. Then, for each gene, the model was extended by
including the log-fold-change as a covariate. The effect of
the covariate was modeled by using fractional polynomials
of order two, which allow flexible modeling of the effect [21].
The statistical significance of the effect was then tested by
using the likelihood ratio test.
All the applied tests were two-sided. Given that a number of
genes were tested, gene-specific p values were corrected for
multiple testing by using Hommel’s method [22] with the aim
to preserve the overall 5 % level of significance. The analyses




A total of 109 early stage NSCLC patients aged from 39.8 to
78.1 years (mean 61.8, standard deviation 8.4 years) were
included in the study. The majority of the patients (77.1 %)
were males. Among the patients, 36 (33.0 %) had lung ade-
nocarcinoma (AdC), 48 (44.0 %) had squamous cell carcino-
ma (SqCC), and the remaining 25 (23.0 %) had large cell
carcinoma (LCC) of the lung. Fifty-three (48.6 %) patients
had TNM stage I disease: 18 (16.5 %) with stage IA and 35
(32.1 %) with stage IB. Fifty-six patients (51.4 %) had stage II
disease: 25 (22.9 %) with stage IIA and 31 (28.5 %) with stage
IIB. The median follow-up time was equal to 48.8 months.
During the follow-up, 49 patients had disease recurrence and
36 of them had died.
Differential gene expression between tumor and non-tumor
lung tissues
The expression of 23 different genes was analyzed simulta-
neously in each sample using a TaqMan low density array
analysis from Applied Biosystems. We were unable to suc-
cessfully amplify a number of gene transcripts in some cases
possibly due to their tissue level below the detection limit of
the assay. As a result, for none of the genes, the log-fold-
change could be defined for all the patients. Twenty out of 23
analyzed genes showed statistically significant differences in
expression between tumor and non-tumor tissues (Table 2).
Table 1 (continued)
No. Gene symbol Gene Ida Gene product official name (aliases) Gene product functions References
20. TNF 11892 Tumor necrosis factor (TNF
superfamily, member 2)
A multifunctional pro-inflammatory
cytokine involved in the regulation




21. ITGA5 6141 Integrin, alpha 5 (Fibronectin
receptor, alpha polypeptide)
A member of integrin family of membrane
receptors involved in cell adhesion
[17]
22. ITGB3 6156 Integrin, beta 3 (platelet glycoprotein
IIIa, AntigenCD61)
A member of integrin family of membrane
receptors involved in cell adhesion
[17]
23. ITGB1 6153 Integrin, beta 1 (Fibronectin receptor) A member of integrin family of membrane
receptors involved in cell adhesion
[17]
a According to HUGO Gene Nomenclature Committee (HGNC)
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For 13 genes (ITGB1, ITGB3, CXCL1, CXCL9, CXCL10,
CXCL12, CXCR3, CXCR4, TNFA, CHKA, AGFG1, SLC2A1,
and CTC1), the expression in the tumor was lower than in the
normal sample, and for 7 genes (ITGA5, IL8, IL6, CXCL2,
Table 2 Log-fold-changes in gene expression level between tumor and non-tumor lung tissue (the All NSCLC column) and the differences in the log-
fold-change between SqCC and LCC (the SqCC vs. LCC column) and between AdC and LCC (the AdC vs. LCC column)










AGFG1 98 −0.0298±0.1226 0.00011 0.124±0.0278 0.00004 0.0564±0.0293 0.11439
CHKA 88 −0.0235±0.1371 0.00004 0.159±0.0311 0.00001 0.0545±0.0322 0.18784
CXCL1 70 −0.0438±0.1461 0.00045 0.141±0.0324 0.00006 0.0695±0.0339 0.08631
CXCL10 69 −0.0492±0.1558 0.00001 0.179±0.0355 0.00001 0.0799±0.0366 0.06389
CXCL11 100 0.0040±0.1412 0.00001 0.173±0.0386 0.00004 0.0700±0.0397 0.16256
CXCL12 100 −0.0283±0.1418 0.00010 0.163±0.0313 0.00001 0.0620±0.0327 0.12277
CXCL2 102 0.0613±0.1436 0.00001 0.145±0.0322 0.00004 0.0343±0.0341 0.63402
CXCL3 84 0.0385±0.1357 0.00001 0.143±0.0318 0.00004 0.0197±0.0334 1.00000
CXCL5 74 0.0493±0.1658 0.01198 0,122±0.0465 0.02066 0.0355±0.0474 0.91205
CXCL6 19 −0.0247±0.1674 0.13503 0.181±0.0719 0.02940 0.1365±0.0763 0.15835
CXCL9 93 −0.0723±0.1449 0.00001 0.143±0.0342 0.00013 0.0546±0.0359 0.26377
CXCR2 47 0.0485±0.1626 0.18719 −0.564±0.3973 0.31830 −0.6288±0.4194 0.27431
CXCR3 26 −0.0114±0.1613 0.00122 0.245±0.0503 0.00002 0.1259±0.0510 0.03375
CXCR4 97 −0.0278±0.1358 0.00003 0.154±0.0311 0.00001 0.0667±0.0326 0.08614
IL10 44 −0.0485±0.1400 0.09305 0.119±0.0448 0.01949 0.0378±0.0460 0.82759
IL6 103 0.0403±0.1527 0.00007 0.153±0.0349 0.00005 0.0585±0.0368 0.22936
IL8 101 0.0075±0.1340 0.02278 0.111±0.0326 0.00196 0.0396±0.0345 0.50733
ITGA5 103 0.0085±0.1146 0.00407 0.109±0.0265 0.00015 0.0448±0.0280 0.22635
ITGB1 105 −0.0314±0.1224 0.00001 0.140±0.0267 0.00001 0.0511±0.0281 0.14398
ITGB3 94 −0.0228±0.1660 0.00005 0.194±0.0369 0.00001 0.0806±0.0388 0.07992
SLC2A1 83 −0.1353±0.1320 0.00001 0.079±0.0325 0.03216 0.0831±0.0342 0.03384
CTC1 88 −0.0189±0.1265 0.00018 0.139±0.0296 0.00002 0.0565±0.0307 0.13756
TNFA 4 −0.0009±0.1956 0.01730 0.342±0.0792 0.00533 0.1721±0.0548 0.01745
Italics indicate p-values that are significant while controlling the overall significance level at 0.05
a Overall sample mean
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Fig. 1 Left: The estimated overall survival probability. Right: The estimated disease-free survival probability
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CXCL3, CXCL5, and CXCL11), an increase in expression in
tumor was observed (Table 2).
The analysis of the effect of age, gender, TNM stage, or
histological type on gene expression revealed that only histolog-
ical type had substantial influence on the log-fold-change. In
particular, for all the genes except of CXCL5, CXCL6, CXCR2,
IL10, and SLC2A1, the effect of histological type was statistically
significant at the 5 % significance level (after adjusting the gene-
specific p-values for multiple testing). In general, for the genes
for which histological type had a significant effect, the log-fold-
change in SqCC was statistically significantly higher than in
AdC or LCC. For the latter two types, the log-fold-change was
not statistically significantly different, except of genes CXCR3
and TNF, for which the change was higher for AdC than for
LCC. The results are summarized in Table 2.
Analysis of overall survival
In the group of 109 analyzed patients, 36 deaths were ob-
served. The median follow-up time was equal to 48.8 months.
The left hand side panel of Fig. 1 presents the OS curve for the
whole group of analyzed patients.
In the proportional hazards model including patients’ age,
gender, TNM stage of the disease (I vs. II), and histological
type of tumor, only TNM stage was found to be statistically
significantly influencing OS (Table 3). In the model simplified
by retaining only TNM, the hazard ratio (HR) for TNM II vs. I
was estimated to be equal to 7.5 (95% confidence interval, CI:
[3.09, 18.29]; p<0.001). When the model containing TNM
was extended by including the gene-specific log-fold-change
for each gene separately as a covariate, only the effect of
CXCL5 was found to be statistically significant (multiple-
testing-corrected p=0.04). Five of the genes (CXCL6,CXCR2,
CXCR3, IL10, and TNF) were excluded from the survival
analyses due to the lack of expression data for more than
50 % of the patients.
The association between the logarithmically transformed
OS hazard ratio and log-fold-change in the CXCL5 expression
between the tumor and normal lung tissue is shown in Fig. 2
(the panel of the left-hand side). The estimated form of the
dependence of the log-HR on the log-fold-change of CXCL5
is presented as a solid line. To provide information about the
individual patient values of the log-fold-change, deviations
(indicated by the closed circles) from the predicted log-HR
curve for individual patients were added to the plot. The
sudden drop of the curve at the left hand side is mainly due
to a single observation (not shown on the plot) for a TNM IIA
patient with the log-fold-change of −0.36, whowas alive at the
last follow-up visit at around 36 months postsurgery. If we
disregard this boundary effect, the plot suggests that the
hazard of death continuously decreases with the increasing
fold change for the gene. The plot does not suggest any
particular threshold value for the log-fold-change.
For illustrative purposes, in the right hand side panel of
Fig. 2, we present the OS curves for two groups of patients
created arbitrarily by considering the log-fold-change below
or above the observed median (0.0794). The curves indicate
the higher risk of death for the patients with the log-fold-
change below 0.0794, i.e., with the gene expression in the
tumor tissue smaller than exp(0.0794)=1.08 times the expres-
sion in the normal tissue.
Analysis of disease-free survival
In the group of 109 analyzed patients, there were 49 deaths
and disease recurrences. Figure 1 (the panel on the right-hand
side) presents the DFS curve for the whole group of patients.
In the proportional hazards model including patients’ age,
gender, TNM stage (I vs. II) of the disease, and histological
type of tumor, only TNM stage was found to statistically
significantly influence DFS (Table 3). In the simplified model,
HR for TNM II vs. I was estimated to be equal to 2.68 (95 %
CI: [1.47, 4.90]; p=0.001).
Similar to the results of the OS, a statistically significant
effect of the log-fold-change, adjusted for the effect of TNM,
was found only for gene CXCL5 (multiple-testing-corrected
p=0.004). The left-hand-side panel of Fig. 3 presents the
estimated form (solid line) of the dependence of the log-HR
Table 3 Multivariable analysis of the prognostic effect of patients’ clinicopathological characteristics on overall survival and disease-free survival
(proportional hazards model)
Variable Overall survival Disease-free survival
Hazard ratio p-value 95 % Confidence interval Hazard ratio p-value 95 % Confidence interval
Age 1.0057 0.787 0.9652–1.0478 1.0099 0.573 0.9757–1.0453
Gender 0.5145 0.121 0.2221–1.1916 0.6242 0.182 0.3126–1.2466
TNM II 9.8231 <0.001 3.7889–25.4677 3.1955 <0.001 1.6640–6.1366
AdC 1.3598 0.444 0.6190–2.9874 1.4219 0.297 0.7333–2.7573
LCC 1.9305 0.122 0.8386–4.4440 1.4579 0.321 0.6923–3.0703
Italics indicate p values <0.05
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on the log-fold-change for CXCL5. The shape of the curve is
very similar to the one shown in Fig. 3 for OS and suggests
that the hazard of disease recurrence continuously decreases
with the increasing fold change in the gene expression. For
illustrative purposes, in the right hand side panel of Fig. 3, we
present the DFS curves for two groups of patients created by
considering the log-fold-change below or above the observed
median (0.0794). The curves indicate the higher risk of dis-
ease recurrence for the patients with the log-fold-change in the
CXCL5 expression below the median value.
Discussion
The aim of the study was to evaluate the expression of 23
genes as putative prognostic markers in early stage NSCLC.
Twenty-three genes had been selected for the examination.
These included three genes evaluated by microarray approach
(AGFG1/HRB, STC1, and SLC2A1) that overlap between
NSCLC prognostic signatures, CHKA suggested as a new
prognostic predictor in early stage NSCLC: three genes
encoded for intergins α5, β3, and β1 which had been prog-
nostic in the comprehensive analysis of 15 integrin genes by
Dingemans et al. [17]: and 16 genes for cytokines or their
receptors that have been previously implicated in lung cancer
biology [11, 23, 24] and/or demonstrated to be a part of a
prognostic signature [12, 15]. A relative quantification RT-
PCR method was applied as a research method. The method
allows estimation of the fold changes in gene expression
between tumor and non-tumor lung tissues from the same
patient and is widely used for microarray data verification
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Fig. 2 Left: The estimated form (solid line) of the dependence of the OS
log-HR on the log-fold-change of CXCL5. The shaded region indicates the
95 % CI limits. The closed circles indicate deviations from the predicted
log-HR curve for individual patients and provide an information about the
individual patient values of the log-fold-change. Right: The estimated OS
curves for two groups of patients with the log-fold-change below or above
the observed median (0.0794). The plots are based on data for 74 patients
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Fig. 3 Left: The estimated form (solid line) of the dependence of the DFS
log-HR on the log-fold-change of CXCL5. The shaded region indicates the
95 % CI limits. The closed circles indicate deviations from the predicted
log-HR curve for individual patients and provide an information about the
individual patient values of the log-fold-change. Right: The estimated DFS
curves for two groups of patients with the log-fold-change below or above
the observed median (0.0794). The plots are based on data for 74 patients
with available information about the expression of the gene
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TaqMan low density array analysis that allows a simultaneous
examination of the expression of dozens of different genes in
each sample was used [5].
In our study, the expression of the majority of the analyzed
genes (20 out of 23) in tumor and matched normal lung tissues
differed statistically significantly after applying a multiple-
testing correction. Among the differentially expressed genes,
there were integrin genes ITGA5, ITGB3, and ITGB1; genes
for cytokines or their receptors CXCL1, CXCL2, CXCL3,
CXCL5, CXCL9, CXCL10, CXCL11, CXCL12, CXCR3,
CXCR4, IL6, IL8, and TNF; a choline kinase alpha gene
CHKA; as well as genes AGFG1 and CTC1 encoded for
nucleoporin-like protein and stanniocalcin-1 (SLC2A1), re-
spectively. On the other hand, tumor-associated alterations
of the expression level of 3 genes (CXCL6, CXCR2, and
IL10) did not reach statistical significance.
Changes in gene expression were more pronounced in
SqCC as compared with AdC or LCC. On the other hand,
no significant differences in gene expression in tumor related
to matched non-tumor lung tissue were found between AdC
and LCC samples, except for the activity of TNF and CXCR3.
Based on these results, the analyzed genes seem to be in-
volved in the process of NSCLC evolution, especially in the
case of SqCC of the lung, but further examinations are neces-
sary to clarify their contribution to tumor growth and
progression.
However, we failed to evaluate the expression of particular
genes in some cases possibly due to their tissue level below
the detection limit of the assay. Similar results were reported
by Seike et al. who had been unable to detect TNF-α and
interleukin (IL)-10 expression in a significant percentage of
examined tumor and non-tumor tissues [15]. Of interest, the
lack of IL-10 expression in specimens from stage I NSCLC
patients was found to be associated with significantly worse
outcome [16].
One of the major goals of our study was to evaluate the
prognostic significance of the tumor-associated alterations in
the expression level of the 23 selected genes in stages I and II
NSCLCs. In the analyses of OS and DFS, five genes (CXCL6,
CXCR2, CXCR3, IL10, and TNF) had to be excluded from the
evaluations due to lack of the expression data for more than
50 % of the patients. For the remaining 18 genes, only the
expression of one gene (CXCL5) was statistically significantly
associated with patients’ overall and disease-free survival after
applying a multiple-testing correction (p=0.04 and p=0.004,
respectively). Upregulation of CXCL5 expression in tumor
was found to be a favorable prognostic factor for both OS
and DFS, and none of the analyzed clinicopathologic charac-
teristics (patients’ age, gender, stage, or tumor histological
type) influenced these associations. Gene product CXCL5
(also known as ENA-78/SCYB-5) is a CXC-type chemo-
attractive cytokine that was primary described as a powerful
attractant for granulocytes and an inflammatorymediator [26].
More recently, CXCL5 contribution to cancer growth and
metastasis has been demonstrated [24, 27]. Specifically,
CXCL5 has been found to be important in mediating tumor-
associated angiogenesis [12, 28] as well as in promoting
growth, migration, and invasion of tumorigenic cell lines
derived from NSCLC [29] and other cancers [30–32]. The
CXCL5 expression has been shown to be elevated at both
mRNA and protein levels and affect patients’ survival in a
number of human tumors, including in pancreatic [31, 33],
colorectal [34], breast [35], ovarian [36], or prostate [30]
carcinomas. However, survival data are limited and inconsis-
tent [31, 37–39]. In the study of White et al., risk of the
recurrence after lung cancer resection in NSCLC patients’
was found to be associated with enhanced expression of the
sum angiogenic CXC chemokines [12].
In contrast to CXCL5, none of the remaining genes exam-
ined in our study was found to be associated with patients’
postoperative outcome. It has been repeatedly emphasized
that the direct comparison of gene expression data is difficult
because potential variations in applied analytical methods and
patient selection algorithms may greatly compromise the re-
producibility of the results [3, 9, 40, 41]. The analysis of gene
expression signatures reported for a defined tumor phenotype
or patients’ prognosis reveals very minimal overlapping be-
tween them in terms of gene identity. Although a particular
signature validation on several independent sample sets gen-
erally demonstrated high degree of reproducibility [42], cross-
examination of public available gene expression data by dif-
ferent statistical methods generated different results [40, 43].
RT-PCR-based gene expression studies usually used for
microarray-based data validation often failed to confirm the
examined effect of the gene. Consequently, in the recent
critical review of 16 published studies reporting the develop-
ment of the gene expression-based prognostic signatures in
NSCLC, Subramanian and Simon found little evidence that
any of the signatures are ready for clinical application [3].
Besides, when effects of multiple genes are investigated, high
probability of false-positive finding exists if multiple-testing
correction methods are not applied. To illustrate, in the study
by Lau et al., who examined 158 putative prognostic genes in
a cohort of 147 surgically treated NSCLC patients with RT-
PCR method, 24 genes influenced patients’ survival, but the
effect of only five of them remained significant after the false
discovery rate adjustment for multiple testing [44]. Thus,
multiple-testing corrections are very important to properly
control the overall probability of a false-positive finding.
In conclusion, in our study, 18 out of the 23 genes previ-
ously found to be relevant for NSCLC formation and/or early
staged NSCLC patients’ postoperative outcome demonstrated
differential expression in tumor and matched unaffected lung
tissues. Changes in expression were more pronounced in
squamous carcinomas as compared to tumors of non-
squamous histology, pointing out the possible contribution
4626 Tumor Biol. (2014) 35:4619–4628
of the genes to SqCC carcinogenesis. Among the 23 genes
previously suggested to be relevant for early staged NSCLC
patients’ postoperative outcome, only CXCL5 showed a sta-
tistically significant prognostic effect.
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